359 related articles for article (PubMed ID: 18516025)
21. Chemotherapy for metastatic colorectal cancer.
Rosales J; Leong LA
J Natl Compr Canc Netw; 2005 Jul; 3(4):525-9. PubMed ID: 16038643
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Ducreux M; Louvet C; Bekradda M; Cvitkovic E
Semin Oncol; 1998 Apr; 25(2 Suppl 5):47-53. PubMed ID: 9609108
[TBL] [Abstract][Full Text] [Related]
23. [Successes in late solid tumors. New therapy offer].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
[No Abstract] [Full Text] [Related]
24. [A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Kawakami H; Satoh T; Nakagawa K
Nihon Rinsho; 2011 Apr; 69 Suppl 3():439-45. PubMed ID: 22214001
[No Abstract] [Full Text] [Related]
25. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
26. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Van Cutsem E; Geboes K
Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
[TBL] [Abstract][Full Text] [Related]
27. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
Robertson JD; Botwood NA; Rothenberg ML; Schmoll HJ
Clin Colorectal Cancer; 2009 Jan; 8(1):59-60. PubMed ID: 19203899
[TBL] [Abstract][Full Text] [Related]
28. [Chemotherapy of elderly patients with colorectal cancer].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Jun; 53(2):97-105. PubMed ID: 19581175
[TBL] [Abstract][Full Text] [Related]
29. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Chu E; Schulman KL; McKenna EF; Cartwright T
Clin Colorectal Cancer; 2010 Oct; 9(4):229-37. PubMed ID: 20920995
[TBL] [Abstract][Full Text] [Related]
30. Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Morse MA
IDrugs; 2005 Dec; 8(12):974-7. PubMed ID: 16320126
[No Abstract] [Full Text] [Related]
31. An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
Schrag D; Weiser M; Schattner M; Shia J; Akhurst T
J Clin Oncol; 2005 Mar; 23(9):1799-802. PubMed ID: 15774773
[No Abstract] [Full Text] [Related]
32. On 5-fluorouracil therapy of colorectal cancer.
Jensen SA
Dan Med J; 2013 Jul; 60(7):B4603. PubMed ID: 23809976
[No Abstract] [Full Text] [Related]
33. Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
Gibson TB; Grothey E; Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):233-9. PubMed ID: 18650191
[No Abstract] [Full Text] [Related]
34. NCCN guideline updates: colon and rectal cancers, version 1.2004.
National Comprehensive Cancer Network
J Natl Compr Canc Netw; 2004 Jul; 2(4):284-5. PubMed ID: 19795595
[No Abstract] [Full Text] [Related]
35. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
36. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
[TBL] [Abstract][Full Text] [Related]
37. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM
Clin Colorectal Cancer; 2005 Nov; 5(4):292-4. PubMed ID: 16356309
[No Abstract] [Full Text] [Related]
38. Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
Maung K
Clin Colorectal Cancer; 2003 Nov; 3(3):150-3. PubMed ID: 14706173
[No Abstract] [Full Text] [Related]
39. [Chemotherapy of patients with colorectal carcinoma].
Punt CJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(26):1441-7. PubMed ID: 16010954
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
Booth C
J Clin Oncol; 2008 Oct; 26(28):4693-4; author reply 4694-5. PubMed ID: 18824719
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
